Anti-vascular endothelial growth factor treatment for eye diseases

BMJ (Online)

Volumn 344, Issue 7855, 2012, Pages

  Cheung, Ning ^a   Lam, Dennis S C ^a   Wong, Tien Y ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR;

ANTIANGIOGENIC ACTIVITY; BLEEDING; BLINDNESS; CATARACT; COST EFFECTIVENESS ANALYSIS; DIABETIC RETINOPATHY; DRUG COST; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; EDITORIAL; ENDOPHTHALMITIS; EYE DISEASE; GLAUCOMA; HUMAN; INFECTION; NEOPLASM; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA VEIN OCCLUSION; STROKE; THROMBOEMBOLISM; VITREOUS HEMORRHAGE; DRUG ANTAGONISM; RETINA DISEASE;

ANGIOGENESIS INHIBITORS; HUMANS; RETINAL DISEASES; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84860640197     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e2970     Document Type: Editorial

References (12)

1. Rosenfeld PJ. Bevacizumab versus ranibizumab for AMD. N Engl J Med 2011;364:1966-7.
2. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010;376:124-36.
3. Wong TY, Scott IU. Clinical practice. Retinal-vein occlusion. N Engl J Med 2010;363:2135-44.
4. Cheung N, Wong TY. Changing trends of blindness: the initial harvest from translational public health and clinical research in ophthalmology. Am J Ophthalmol 2012;153:193-5.
5. Keenan TD, Wotton CJ, Goldacre MJ. Trends over time and geographical variation in rates of intravitreal injections in England. Br J Ophthalmol 2012;96:413-8.
6. Lim JH, Wickremasinghe SS, Xie J, Chauhan DS, Baird PN, Robman LD, et al. Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. Am J Ophthalmol 2012;153:678-686.e2.
7. Van der Reis MI, La Heij EC, De Jong-Hesse Y, Ringens PJ, Hendrikse F, Schouten JS. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 2011;31:1449-69.
8. Lim LS, Cheung CM, Mitchell P, Wong TY. Emerging evidence concerning systemic safety of anti-VEGF agents - should ophthalmologists be concerned? Am J Ophthalmol 2011;152:329-31.
9. Carneiro AM, Costa R, Falcao MS, Barthelmes D, Mendonça LS, Fonseca SL, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol 2012;90:e25-30.
10. Schmucker C, Loke YK, Ehlken C, Agostini HT, Hansen LL, Antes G, et al. Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. Br J Ophthalmol 2011;95:308-17.
11. Raftery J, Clegg A, Jones J, Tan SC, Lotery A. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 2007;91:1244-6. (Pubitemid 47344908)
12. Ohr M, Kaiser PK. Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin Pharmacother 2012;13:585-91.